中国实用外科杂志2024，Vol.44Issue(10)：1133-1138,6.DOI:10.19538/j.cjps.issn1005-2208.2024.10.11
胃癌术后辅助免疫治疗的风险与获益
Risk and benefit of postoperative adjuvant immunothera-py for gastric cancer
摘要
Abstract
For postoperative adjuvant therapy in patients with locally advanced gastric cancer,immunotherapy has the potential to improve prognosis,but existing evidence still cannot shake the cornerstone position of chemotherapy.Accurately screening potential beneficiaries of immunotherapy is the key to addressing the poor efficacy of adjuvant immunotherapy in the entire population after surgery.It is recommended to first screen the population with potential immune benefits,such as EBV positive,dMMR/MSI-H,and PD-L1 high expression,based on the molecular classification and biomarkers of the tumor.Then,combined with the patient's immune therapy tolerance,postoperative pathological stage,histological classification,and economic family status,the risk and benefit ratio of immune therapy should be comprehensively evaluated to develop the best treatment plan.关键词
胃癌/免疫治疗/辅助治疗/免疫检查点抑制剂/化疗Key words
gastric cancer/immunotherapy/adjuvant therapy/immune checkpoint inhibitors/chemotherapy分类
医药卫生引用本文复制引用
丁明晨,丛琳,蔡洁媛,张小田..胃癌术后辅助免疫治疗的风险与获益[J].中国实用外科杂志,2024,44(10):1133-1138,6.基金项目
国家自然科学基金项目(No.82272627) （No.82272627）
国家卫生改善和研究基金项目(No.2024-1-1021) （No.2024-1-1021）
北京市自然科学基金项目(No.L234003,No.Z200015) （No.L234003,No.Z200015）
内蒙古医学科学院公立医院科研联合基金科技项目(No.2023GLLH0132) （No.2023GLLH0132）
北京大学肿瘤医院内蒙古校区公立医院改革与质量发展示范项目(胃肠道肿瘤)科研基金(No.2023SGGZ068) （胃肠道肿瘤）
